Applied Molecular Transport Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Applied Molecular Transport's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 17.4% annually.
Belangrijke informatie
-25.6%
Groei van de winst
13.3%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | n/a |
Rendement op eigen vermogen | -460.5% |
Nettomarge | n/a |
Laatste winstupdate | 30 Sep 2023 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation
Mar 07We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate
Nov 13Applied Molecular Transport GAAP EPS of -$0.93
Aug 04Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky
Jul 27Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data
Jul 05Applied Molecular: Interesting Drug Delivery Approach For The GI Tract
May 03We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate
Apr 28We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
Jan 08We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
Aug 29Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans
Apr 05Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?
Feb 11Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation
Dec 21Applied Molecular Transport reports Q3 results
Nov 12Opbrengsten en kosten
Hoe Applied Molecular Transport geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 23 | 0 | -75 | 29 | -11 |
30 Jun 23 | 0 | -93 | 30 | 7 |
31 Mar 23 | 0 | -112 | 32 | 27 |
31 Dec 22 | 0 | -126 | 37 | 45 |
30 Sep 22 | 0 | -134 | 37 | 64 |
30 Jun 22 | 0 | -135 | 37 | 64 |
31 Mar 22 | 0 | -122 | 35 | 58 |
31 Dec 21 | 0 | -100 | 29 | 41 |
30 Sep 21 | 0 | -89 | 25 | 58 |
30 Jun 21 | 0 | -80 | 20 | 27 |
31 Mar 21 | 0 | -72 | 16 | 23 |
31 Dec 20 | 0 | -67 | 13 | 54 |
30 Sep 20 | 0 | -55 | 10 | 30 |
30 Jun 20 | 0 | -46 | 7 | 46 |
31 Mar 20 | 0 | -38 | 6 | 33 |
31 Dec 19 | 0 | -28 | 4 | 24 |
Kwaliteitswinsten: AMTI is currently unprofitable.
Groeiende winstmarge: AMTI is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AMTI is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Versnelling van de groei: Unable to compare AMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: AMTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Rendement op eigen vermogen
Hoge ROE: AMTI has a negative Return on Equity (-460.5%), as it is currently unprofitable.